Acadia Pharmaceuticals (ACAD) FY2015 results: revenue $61,000, down 49.2% on the year
Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $61,000 for fiscal 2015, the year ended 31 December 2015, down 49.2% on the year before. Net income was -$164 million, and diluted earnings per share $-1.63. The figures are the company's own, from the 10-K it filed with the SEC on 29 February 2016.
Revenue
$61,000
-49.2% on the year
FY2009FY2015
Operating margin
-269855.7%
-77691.7% a year earlier
FY2009FY2015
Net income
-$164 million
FY2009FY2015
Diluted EPS
-$1.63
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
0.1
0.1
1.1
-49.2%
Research and development
73.9
60.6
26.7
+21.9%
Selling, general and administrative
88.3
32.7
n/a
+169.6%
Operating income
-165
-93.2
-38.3
Operating margin
-269855.7%
-77691.7%
-3344.7%
Pre-tax income
-164
-92.5
-37.9
Income tax
0.3
0.0
0.0
Net income
-164
-92.5
-37.9
Net margin
-269578.7%
-77062.5%
-3314.2%
Diluted EPS
-$1.63
-$0.95
-$0.44
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
-122
-66.4
-31.8
Capital expenditure
2.1
0.2
0.6
+1,089.4%
Free cash flow
-124
-66.6
-32.4
Free cash flow margin
-203173.8%
-55511.7%
-2828.6%
Depreciation and amortisation
0.6
0.2
0.1
+214.1%
Share-based compensation
40.2
16.0
5.7
+150.6%
Shares outstanding at period end
102m
100m
91m
+1.9%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
200
309
182
-35.5%
Other liabilities
22.1
16.0
7.0
+38.6%
Total liabilities and equity
222
325
189
-31.8%
Fixed assets
2.2
0.6
0.6
+298.4%
Investments
113
261
174
-56.6%
Cash and equivalents
102
61.9
11.7
+65.1%
Other assets
4.6
2.4
2.7
+88.5%
Total assets
222
325
189
-31.8%
10-K for the year ended 31 December 2015, filed 29 February 2016: the filing.